100% Quality Guarantee
PhD-Level Technical Support
Human APP Recombinant Protein (N-GST)
Key Features

Human APP Recombinant Protein (N-GST) (GXRP03365)

SKU GXRP03365
Product Type Recombinant Protein
Species Human
Expression System E. coli
Tag N-GST
$458 - $2,412

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human APP Recombinant Protein (N-GST)

Human APP Recombinant Protein (N-GST) is a recombinant protein expressed in E. coli, spanning Asp672-Val711, with an N-terminal GST tag. Predicted molecular weight: 31.14 kDa. Purity: >90% as determined by SDS-PAGE. Supplied lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Applications: ELISA, immunogen, SDS-PAGE and Western blot. Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. For research use only.

Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi).

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose